Developer docs
API playgroundTry for free, no card

Search company profiles

Alphamab Oncology

Full company profile

uuid000431l

Namestring
Alphamab Oncology
Legal namestring
江苏康宁杰瑞生物制药有限公司
Websiteurl
alphamabonc.com
Company typeenum
Public
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSuzhou, China
HQ citystring
Suzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology biopharmaceuticals, bispecific antibodies, antibody-drug conjugates, subcutaneous antibody formulations, immuno-oncology therapeutics
Industry5 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAKAFAJ
Breast Oncology
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from the sale of approved biopharmaceutical products including KN035 (envafolimab), China's first approved subcutaneously administered PD-L1 inhibitor. The company derives the majority of its revenue from product sales in the Chinese pharmaceutical market.

Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1恩维达®
Description

Brand name for KN035 (envafolimab), the globally first subcutaneous PD-L1 inhibitor.

alphamabonc.com
+1 more record
Core offering1 text field

Alphamab Oncology discovers, develops, manufactures, and commercializes innovative oncology biopharmaceuticals built on proprietary bispecific antibody and antibody-drug conjugate (ADC) platforms. Its commercial portfolio includes KN035 (Envafolimab), the world's first subcutaneously administered PD-L1 inhibitor, and KN026 (Anbenitamab), China's first domestically developed HER2 bispecific antibody, alongside a clinical pipeline of biparatopic and bispecific ADCs and fusion proteins for solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • China's first approved subcutaneously administered PD-L1 inhibitor
+2 more records
Product overview1 text field

Alphamab Oncology is a biopharmaceutical company focused on oncology drug development. The company has developed a portfolio of innovative biologics including: (1) Two approved products - Envarki® (KN035/Envafolimab, the world's first subcutaneous PD-L1 inhibitor) and Enitu® (KN026/Anbenitamab, China's first domestically developed HER2 bispecific antibody); (2) A pipeline of bispecific antibodies and antibody-drug conjugates (ADCs) including JSKN003 (biparatopic HER2 ADC), JSKN016 (TROP2/HER3 bispecific ADC), JSKN021 (EGFR/HER3 dual payload ADC), JSKN022 (PD-L1/αvβ6 bispecific ADC), JSKN027 (PD-L1/VEGFR2 bispecific ADC), and JSKN033 (subcutaneous ADC formulation); and (3) KN046 (PD-L1/CTLA-4 bispecific antibody) and KN019 (B7-CTLA4 fusion protein). The company leverages multiple proprietary technology platforms including glycan site-specific conjugation, linker-payload, dual-payload ADC, bispecific antibody (CRIB platform), high-concentration subcutaneous formulation, and single-domain antibody platforms.

Product and service10 records
1KN035 (Envafolimab) / Envarki (恩维达)
CategoryOncology Biopharmaceutical / PD-L1 Inhibitor
Description

A single-domain antibody PD-L1 inhibitor providing convenient subcutaneous injection administration for cancer treatment, offering improved patient compliance compared with intravenous infusion. Approved for use in patients with solid tumors including gastric cancer and other PD-L1 expressing malignancies.

2KN026 (Anbenitamab) / Enitu (恩尼妥)
CategoryOncology Biopharmaceutical / HER2 Bispecific Antibody
Description

China's first domestically developed HER2 bispecific antibody using the CRIB platform technology to simultaneously bind two non-overlapping epitopes of the HER2 receptor (domain IV and domain II), blocking HER2 signaling and inducing receptor aggregation for enhanced ADCC and CDC effects. Indicated for HER2-positive gastric cancer and being developed for HER2-positive breast cancer.

3JSKN003
CategoryOncology Biopharmaceutical / Antibody-Drug Conjugate
Description

Biparatopic HER2-targeting antibody-drug conjugate (ADC) using the company's glycan site-specific conjugation platform to deliver cytotoxic payloads to HER2-positive tumor cells. Has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from Chinese and US authorities for platinum-resistant ovarian cancer and HER2-positive colorectal cancer.

4JSKN016
CategoryOncology Biopharmaceutical / Bispecific Antibody-Drug Conjugate
Description

TROP2/HER3 bispecific antibody-drug conjugate targeting TROP2 and HER3 receptors, in clinical development for triple-negative breast cancer (TNBC) and other solid tumors. Phase III clinical trial initiated in March 2026.

5JSKN021
CategoryOncology Biopharmaceutical / Dual-Payload Bispecific ADC
Description

EGFR/HER3 dual payload bispecific ADC, the company's first dual-payload ADC to enter clinical stage, combining EGFR and HER3 targeting with dual payload delivery technology. IND application accepted by China's CDE in March 2026.

6JSKN022
CategoryOncology Biopharmaceutical / Bispecific Antibody-Drug Conjugate
Description

PD-L1/αvβ6 bispecific antibody-drug conjugate, described as the world's first PD-L1/αvβ6 bispecific ADC to enter clinical stage, in development for advanced malignant solid tumors. Phase I initiated October 2025.

7JSKN027
CategoryOncology Biopharmaceutical / Bispecific Antibody-Drug Conjugate
Description

PD-L1/VEGFR2 bispecific antibody-drug conjugate for advanced malignant solid tumors, combining PD-L1 targeting with VEGFR2 inhibition. IND application accepted by China's CDE.

8JSKN033
CategoryOncology Biopharmaceutical / Subcutaneous ADC Combination
Description

Subcutaneous injection formulation combining JSKN003 and envafolimab (KN035) for subcutaneous administration of HER2-targeting ADC therapy, leveraging the company's high-concentration subcutaneous formulation platform.

9KN046
CategoryOncology Biopharmaceutical / PD-L1 x CTLA-4 Bispecific Antibody
Description

PD-L1/CTLA-4 bispecific antibody with a proprietary design combining CTLA-4 and PD-L1 single-domain antibodies, targeting PD-L1 high-expressing tumor microenvironments and clearing immunosuppressive Treg cells. Has received FDA Orphan Drug Designation for thymic epithelial tumors.

10KN019
CategoryBiopharmaceutical / B7-CTLA4 Fusion Protein
Description

B7-CTLA4 dual-targeting fusion protein for autoimmune and cancer applications.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1思路迪医药 (3D Medicines)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensing agreement for KN035 (envafolimab) with 3D Medicines (思路迪医药). Under this partnership, Alphamab Oncology granted rights to 3D Medicines for the development and commercialization of KN035, China's first subcutaneously administered PD-L1 inhibitor, in specified territories.

2石药集团/上海津曼特 (CSPC Pharmaceutical Group / Shanghai Jinmant Biotechnology)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partnership for KN026, a bispecific antibody candidate. Alphamab Oncology collaborates with Shanghai Jinmant Biotechnology (under CSPC Pharmaceutical Group) for the joint development of KN026 for the treatment of HER2-positive solid tumors.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic partnership with ArriVent for the development and potential commercialization of innovative biopharmaceutical candidates in specified territories.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership with Glenmark for the development and commercialization of selected biopharmaceutical products in defined markets.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial collaboration with Sanofi for KN026 in combination with Taxotere (docetaxel). This partnership involves clinical development activities exploring the combination of KN026 with Sanofi products for the treatment of HER2-positive solid tumors.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global oncology major co-developing Enhertu (HER2 ADC) with Daiichi Sankyo and Imfinzi (durvalumab, PD-L1). Comparable as a broad incumbent in PD-L1 and HER2 ADC — both competitive and a potential partner for Alphamab assets.

TypeDirect peer
Description

Hong Kong-listed (9995.HK) Chinese biopharma with a HER2-targeted ADC (disitamab vedotin, 爱地希®) that directly competes with Alphamab's JSKN003 in HER2-positive oncology. Closest direct therapeutic area competitor.

TypeBroad incumbent
Description

Pioneer in HER2-targeted therapy (Herceptin/trastuzumab, Perjeta/pertuzumab, Kadcyla/T-DM1 ADC). Closest established incumbent reference for KN026's HER2 bispecific positioning against standard-of-care.

4Duality Biologics
TypeEmerging player
Description

Emerging Chinese biotech focused on next-generation ADCs with multiple partnership deals (e.g., BMS). Comparable as an early-stage ADC specialist with a complementary technology focus in oncology.

TypeDirect peer
Description

Hong Kong-/US-listed (6160.HK / ONC) Chinese oncology biotech with commercial-stage Brukinsa and tislelizumab. Comparable as a globally active, China-rooted oncology biopharma with multiple commercial products and an extensive pipeline.

TypeBroad incumbent
Description

Global leader in HER2 ADC development (trastuzumab deruxtecan/Enhertu, partnered with AstraZeneca) and a broader oncology franchise. Comparable as the dominant player in Alphamab's most-contested indication (HER2 ADCs).

TypeDirect peer
Description

Hong Kong-listed (1801.HK) Chinese biopharma with PD-1 leader (sintilimab) and a growing bispecific antibody pipeline. Directly comparable business model: Chinese-anchored oncology biologics developer with commercial-stage products and pipeline.

TypeDirect peer
Description

Hong Kong-listed (9926.HK) Chinese biopharma and a leading domestic bispecific antibody developer (e.g., PD-1/VEGF cadonilimab). Highly comparable to Alphamab in bispecific antibody platform focus, oncology pipeline, and Chinese commercialization model.

TypeOthers
Description

Hong Kong-listed (1093.HK) Chinese pharma conglomerate that is Alphamab's strategic partner for JSKN003 in mainland China (RMB 3.08B deal). Relevant as both an incumbent Chinese pharma and a counterparty whose commercial execution drives Alphamab's near-term royalty/milestone economics.

10Hansoh Pharmaceutical
TypeDirect peer
Description

Hong Kong-listed (3692.HK) Chinese pharma with a strong oncology biologics franchise. Comparable as a Chinese oncology-focused biopharma with commercialization infrastructure and pipeline depth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alphamab Oncology

Oncology Biopharmaceuticalsalphamabonc.com

Alphamab Oncology firmographics

Firmographics
Name
Alphamab Oncology
Legal name
江苏康宁杰瑞生物制药有限公司
Website
https://alphamabonc.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Alphamab Oncology industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAKAFAJ
Breast Oncology

Keywords

  • Oncology biopharmaceuticals
  • Bispecific antibodies
  • Antibody-drug conjugates
  • Subcutaneous antibody formulations
  • Immuno-oncology therapeutics

Where Alphamab Oncology is headquartered

Location

Headquarters

HQ city
Suzhou
HQ country
China
HQ region
Asia

Offices3 records

Markets served

Alphamab Oncology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from the sale of approved biopharmaceutical products including KN035 (envafolimab), China's first approved subcutaneously administered PD-L1 inhibitor. The company derives the majority of its revenue from product sales in the Chinese pharmaceutical market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Alphamab Oncology product offering

Product offering

Core offering

Alphamab Oncology discovers, develops, manufactures, and commercializes innovative oncology biopharmaceuticals built on proprietary bispecific antibody and antibody-drug conjugate (ADC) platforms. Its commercial portfolio includes KN035 (Envafolimab), the world's first subcutaneously administered PD-L1 inhibitor, and KN026 (Anbenitamab), China's first domestically developed HER2 bispecific antibody, alongside a clinical pipeline of biparatopic and bispecific ADCs and fusion proteins for solid tumors.

Product overview

Alphamab Oncology is a biopharmaceutical company focused on oncology drug development. The company has developed a portfolio of innovative biologics including: (1) Two approved products - Envarki® (KN035/Envafolimab, the world's first subcutaneous PD-L1 inhibitor) and Enitu® (KN026/Anbenitamab, China's first domestically developed HER2 bispecific antibody); (2) A pipeline of bispecific antibodies and antibody-drug conjugates (ADCs) including JSKN003 (biparatopic HER2 ADC), JSKN016 (TROP2/HER3 bispecific ADC), JSKN021 (EGFR/HER3 dual payload ADC), JSKN022 (PD-L1/αvβ6 bispecific ADC), JSKN027 (PD-L1/VEGFR2 bispecific ADC), and JSKN033 (subcutaneous ADC formulation); and (3) KN046 (PD-L1/CTLA-4 bispecific antibody) and KN019 (B7-CTLA4 fusion protein). The company leverages multiple proprietary technology platforms including glycan site-specific conjugation, linker-payload, dual-payload ADC, bispecific antibody (CRIB platform), high-concentration subcutaneous formulation, and single-domain antibody platforms.

Differentiator

Problem solved

Functional benefit

Brands

  • 恩维达®: Brand name for KN035 (envafolimab), the globally first subcutaneous PD-L1 inhibitor.
  • 恩尼妥®

Products and services

  • KN035 (Envafolimab) / Envarki (恩维达) A single-domain antibody PD-L1 inhibitor providing convenient subcutaneous injection administration for cancer treatment, offering improved patient compliance compared with intravenous infusion. Approved for use in patients with solid tumors including gastric cancer and other PD-L1 expressing malignancies.
  • KN026 (Anbenitamab) / Enitu (恩尼妥) China's first domestically developed HER2 bispecific antibody using the CRIB platform technology to simultaneously bind two non-overlapping epitopes of the HER2 receptor (domain IV and domain II), blocking HER2 signaling and inducing receptor aggregation for enhanced ADCC and CDC effects. Indicated for HER2-positive gastric cancer and being developed for HER2-positive breast cancer.
  • JSKN003 Biparatopic HER2-targeting antibody-drug conjugate (ADC) using the company's glycan site-specific conjugation platform to deliver cytotoxic payloads to HER2-positive tumor cells. Has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from Chinese and US authorities for platinum-resistant ovarian cancer and HER2-positive colorectal cancer.
  • JSKN016 TROP2/HER3 bispecific antibody-drug conjugate targeting TROP2 and HER3 receptors, in clinical development for triple-negative breast cancer (TNBC) and other solid tumors. Phase III clinical trial initiated in March 2026.
  • JSKN021 EGFR/HER3 dual payload bispecific ADC, the company's first dual-payload ADC to enter clinical stage, combining EGFR and HER3 targeting with dual payload delivery technology. IND application accepted by China's CDE in March 2026.
  • JSKN022 PD-L1/αvβ6 bispecific antibody-drug conjugate, described as the world's first PD-L1/αvβ6 bispecific ADC to enter clinical stage, in development for advanced malignant solid tumors. Phase I initiated October 2025.
  • JSKN027 PD-L1/VEGFR2 bispecific antibody-drug conjugate for advanced malignant solid tumors, combining PD-L1 targeting with VEGFR2 inhibition. IND application accepted by China's CDE.
  • JSKN033 Subcutaneous injection formulation combining JSKN003 and envafolimab (KN035) for subcutaneous administration of HER2-targeting ADC therapy, leveraging the company's high-concentration subcutaneous formulation platform.
  • KN046 PD-L1/CTLA-4 bispecific antibody with a proprietary design combining CTLA-4 and PD-L1 single-domain antibodies, targeting PD-L1 high-expressing tumor microenvironments and clearing immunosuppressive Treg cells. Has received FDA Orphan Drug Designation for thymic epithelial tumors.
  • KN019 B7-CTLA4 dual-targeting fusion protein for autoimmune and cancer applications.

Quantifiable outcome

  • China's first approved subcutaneously administered PD-L1 inhibitor
  • +2 more outcomes

Companies that use Alphamab Oncology

Customer profile

Segments1 record

Ideal customer profiles2 records

Alphamab Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Alphamab Oncology partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • 思路迪医药 (3D Medicines)coreStrategic or Co-development PartnerLicensing agreement for KN035 (envafolimab) with 3D Medicines (思路迪医药). Under this partnership, Alphamab Oncology granted rights to 3D Medicines for the development and commercialization of KN035, China's first subcutaneously administered PD-L1 inhibitor, in specified territories.
  • 石药集团/上海津曼特 (CSPC Pharmaceutical Group / Shanghai Jinmant Biotechnology)coreStrategic or Co-development PartnerCo-development partnership for KN026, a bispecific antibody candidate. Alphamab Oncology collaborates with Shanghai Jinmant Biotechnology (under CSPC Pharmaceutical Group) for the joint development of KN026 for the treatment of HER2-positive solid tumors.
  • ArriVentminorStrategic or Co-development PartnerStrategic partnership with ArriVent for the development and potential commercialization of innovative biopharmaceutical candidates in specified territories.
  • GlenmarkminorStrategic or Co-development PartnerPartnership with Glenmark for the development and commercialization of selected biopharmaceutical products in defined markets.
  • SanoficoreStrategic or Co-development PartnerClinical trial collaboration with Sanofi for KN026 in combination with Taxotere (docetaxel). This partnership involves clinical development activities exploring the combination of KN026 with Sanofi products for the treatment of HER2-positive solid tumors.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Alphamab Oncology competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: Global oncology major co-developing Enhertu (HER2 ADC) with Daiichi Sankyo and Imfinzi (durvalumab, PD-L1). Comparable as a broad incumbent in PD-L1 and HER2 ADC — both competitive and a potential partner for Alphamab assets.
  • Roche: Pioneer in HER2-targeted therapy (Herceptin/trastuzumab, Perjeta/pertuzumab, Kadcyla/T-DM1 ADC). Closest established incumbent reference for KN026's HER2 bispecific positioning against standard-of-care.
  • Daiichi Sankyo: Global leader in HER2 ADC development (trastuzumab deruxtecan/Enhertu, partnered with AstraZeneca) and a broader oncology franchise. Comparable as the dominant player in Alphamab's most-contested indication (HER2 ADCs).

Direct peers

  • RemeGen: Hong Kong-listed (9995.HK) Chinese biopharma with a HER2-targeted ADC (disitamab vedotin, 爱地希®) that directly competes with Alphamab's JSKN003 in HER2-positive oncology. Closest direct therapeutic area competitor.
  • BeiGene: Hong Kong-/US-listed (6160.HK / ONC) Chinese oncology biotech with commercial-stage Brukinsa and tislelizumab. Comparable as a globally active, China-rooted oncology biopharma with multiple commercial products and an extensive pipeline.
  • Innovent Biologics: Hong Kong-listed (1801.HK) Chinese biopharma with PD-1 leader (sintilimab) and a growing bispecific antibody pipeline. Directly comparable business model: Chinese-anchored oncology biologics developer with commercial-stage products and pipeline.
  • Akeso (Akeso Inc.): Hong Kong-listed (9926.HK) Chinese biopharma and a leading domestic bispecific antibody developer (e.g., PD-1/VEGF cadonilimab). Highly comparable to Alphamab in bispecific antibody platform focus, oncology pipeline, and Chinese commercialization model.
  • Hansoh Pharmaceutical: Hong Kong-listed (3692.HK) Chinese pharma with a strong oncology biologics franchise. Comparable as a Chinese oncology-focused biopharma with commercialization infrastructure and pipeline depth.

Emerging players

  • Duality Biologics: Emerging Chinese biotech focused on next-generation ADCs with multiple partnership deals (e.g., BMS). Comparable as an early-stage ADC specialist with a complementary technology focus in oncology.

Others

  • CSPC Pharmaceutical Group: Hong Kong-listed (1093.HK) Chinese pharma conglomerate that is Alphamab's strategic partner for JSKN003 in mainland China (RMB 3.08B deal). Relevant as both an incumbent Chinese pharma and a counterparty whose commercial execution drives Alphamab's near-term royalty/milestone economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Alphamab Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alphamab Oncology leadership team

Management profile

Number of profiles

Profiles4 records

Alphamab Oncology subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Alphamab Oncology funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alphamab Oncology M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alphamab Oncology

What does Alphamab Oncology do?

Alphamab Oncology discovers, develops, manufactures, and commercializes innovative oncology biopharmaceuticals built on proprietary bispecific antibody and antibody-drug conjugate (ADC) platforms. Its commercial portfolio includes KN035 (Envafolimab), the world's first subcutaneously administered PD-L1 inhibitor, and KN026 (Anbenitamab), China's first domestically developed HER2 bispecific antibody, alongside a clinical pipeline of biparatopic and bispecific ADCs and fusion proteins for solid tumors.

Is Alphamab Oncology a public or private company?

Alphamab Oncology is a public company. It is classified as public and is currently operating.

When was Alphamab Oncology founded?

Alphamab Oncology was founded in 2015. It employs 11 to 50 people.

Where is Alphamab Oncology based?

Alphamab Oncology is headquartered in Suzhou, China, in the Asia region.

How does Alphamab Oncology make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Alphamab Oncology's main competitors?

Broad incumbents on record are AstraZeneca, Roche and Daiichi Sankyo. Direct peers are RemeGen, BeiGene, Innovent Biologics, Akeso (Akeso Inc.) and Hansoh Pharmaceutical. Duality Biologics is listed as an emerging player. CSPC Pharmaceutical Group is listed as an others.

Does Alphamab Oncology have an API?

No public API is recorded for Alphamab Oncology.

What industry is Alphamab Oncology in?

Alphamab Oncology's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingAlphamab Oncology Appoints David Ng as Chief Financial OfficerAlphamab Oncology appointed David Ng as chief financial officer on November 12, 2026, after outgoing CFO Fei Wang resigned. Ng previously led investor relations and capital strategies at HUTCHMED and served as CFO at MEDx Translational Medicine Research. His responsibilities include capital markets strategy, investor relations, and industry competitive analysis.The future of tradingAlphamab Oncology Files Next Day Disclosure Return With HKEX Announcing Share BuybackAlphamab Oncology repurchased 239,000 shares for HKD 1.47 million on November 11, 2026, with prices ranging from HKD 6.045 to 6.195 per share. All repurchased shares will be held as treasury shares.The future of tradingAlphamab Oncology Discloses Share Buyback in HKEX Next Day ReturnAlphamab Oncology repurchased 160,000 ordinary shares for HKD 977,540 on November 3, 2026, with prices ranging from HKD 6.055 to HKD 6.18 per share. All repurchased shares will be held as treasury shares.The future of tradingAlphamab Oncology Files Next-Day Disclosure With HKEX Announcing Share BuybackAlphamab Oncology repurchased 230,000 shares for HKD 1.39 million on November 2, 2026, with purchase prices ranging from HKD 5.985 to HKD 6.12 per share. All repurchased shares will be held as treasury shares.The future of tradingAlphamab Oncology's Anbenitamab Regimen Cuts Progression or Death Risk 54% in Phase III Breast Cancer TrialAlphamab Oncology presented Phase III trial results for anbenitamab at the 2026 ESMO Congress, showing a 54% reduction in progression or death risk in HER2-positive breast cancer. The regimen also prolonged survival in previously treated HER2-positive gastric cancer, and China cleared it for marketing in May 2026.医药魔方-致力于数据赋能医药创新,助力高效决策与数智化转型CSPC, Alphamab's BsADC Shows 100% Confirmed ORR in HER2+ GA/GEJACSPC Pharma and Alphamab Oncology reported early efficacy of anbenitamab repodatecan in first-line HER2+ gastric or GEJA, with confirmed ORR of 71.4% in cohort A, 100% in cohort B, and 50% in cohort C across 25 patients. Safety showed high TRAE rates, with grade 3+ events at 57.1%, 28.6%, and 100% across cohorts, and no treatment-related deaths.AInvestAlphaMAB Oncology - Board resolves to repurchase shares up to HK$ 80 mln in valueAlphaMAB Oncology's board of directors resolved to launch an equity buyback program with a maximum value of HK$80 million, aimed at enhancing shareholder value and optimizing capital structure. The buyback will be executed via open market transactions or other permitted methods, with no timeline or specific terms disclosed.Simply Wall StAlphamab Oncology (SEHK:9966) Stock Rally Meets Revenue Dip And LossesAlphamab Oncology shares rose about 15% over the past month, but H1 2026 results show revenue of ¥271.24m, down from ¥319.44m, with a net loss of ¥40.46m and a basic loss per share of ¥0.04. The company moved from a ¥21.58m profit in H1 2025, while its pipeline spans Phase I, II, III and pre-registration stages.Bamboo WorksAlphamab seals $2.2 billion licensing deal with AI biotechChinese biotech firm Alphamab Oncology has entered a global licensing agreement with U.S.-based AI developer Pathos AI for its candidate cancer drug JSKN016, valuing the deal at up to $2.2 billion. Under the terms, Pathos AI receives exclusive rights outside Greater China and pays an upfront fee of $125 million, providing critical financial relief to Alphamab as it navigates rising R&D costs and recent revenue declines.PharmTechPharmTech Weekly Roundup—August 7, 2026The FDA approved Moderna's mFlusiva, the first mRNA flu vaccine, while the White House released a deregulation blueprint for pharmaceutical manufacturing. In a separate transaction, Pathos AI paid $125 million to Alphamab Oncology for rights to an experimental breast cancer treatment utilizing its AI-driven platform.